AstraZeneca's recently approved ovarian cancer drug Lynparza, or olaparib, can also help men with prostate cancer, according to new clinical trial results on Tuesday. The news is the latest boost to the British company's cancer drug pipeline, which formed a central plank of its defense against a $118 billion takeover attempt by Pfizer last year. AstraZeneca has flagged olaparib as a potential $2-billion-a-year seller, based on ongoing Phase III studies in ovarian, breast, gastric and pancreatic cancers. Olaparib works by blocking an enzyme involved in cell repair and is approved for women with ovarian cancer and hereditary BRCA gene mutations.
via Health News Headlines - Yahoo News http://ift.tt/1yNUWUl
No comments:
Post a Comment